SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
Por:
Majem, M, Garcia-Martinez, E, Martinez, M, Munoz-Couselo, E, Rodriguez-Abreu, D, Alvarez, R, Arance, A, Berrocal, A, de la Cruz-Merino, L, Lopez-Martin, J A
Publicada:
28 ene 2020
Ahead of Print:
28 ene 2020
Resumen:
The use of immune checkpoint inhibitors has emerged as an effective
treatment option for patients with several tumor types. By increasing
the activity of the immune system, they can induce inflammatory side
effects, which are often termed immune-related adverse events. These are
pathophysiologically unique toxicities, compared with those from other
anticancer therapies. In addition, the spectrum of the target organs is
very broad. Immune-inflammatory adverse events can be life threatening.
Prompt diagnosis and pharmacological intervention are instrumental to
avoid progression to severe manifestations. Consequently, clinicians
require new skills to successfully diagnose and manage these events.
These SEOM guidelines have been developed with the consensus of ten
medical oncologists. Relevant studies published in peer-review journals
were used for the guideline elaboration. The Infectious Diseases Society
of America grading system was used to assign levels of evidence and
grades of recommendation.
|